文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

伤寒结合疫苗:抗击抗菌药物耐药的新工具

Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance.
PubMed 文献 · Lancet Infect Dis · 2018-08-28

作者提出更积极的大规模接种(含≤15岁儿童补种及低发病率地区接种)可减少抗菌药物过度使用并降低耐药。

要点

  • 每1例真伤寒对应3–25例非伤寒患者被不必要使用抗菌药物。
  • 传统成本效果分析低估疫苗对减少抗菌药物过度使用与耐药的价值。

核心结论

  • 大规模、更积极的伤寒结合疫苗接种规划有潜力减少抗菌药物过度使用,从而降低多种细菌病原体的耐药。
  • 资助机构与各国政府在决策推广伤寒结合疫苗时应考虑抗菌药物使用与耐药广泛下降的潜在收益。

研究设计与样本

  • 本文为发表于Lancet Infect Dis的综述/观点文章,基于WHO 2018年伤寒结合疫苗推荐及健康经济分析进行论述。

主要发现

  • 疑似伤寒的抗菌药物使用可能是全球耐药出现与传播的重要选择压力。

关键数值与推荐

  • WHO于2018年3月发布推荐,主张在流行国家程序性使用伤寒结合疫苗。
  • 作者建议的大规模接种包括对≤15岁儿童开展补种活动以及在低发病率地区接种。

临床怎么用

  • 在伤寒流行国家应程序性推广伤寒结合疫苗,并考虑将减少抗菌药物过度使用与耐药作为接种规划的附加收益纳入决策。
  • 对非特异性急性发热患者经验性使用抗菌药物前,应权衡伤寒疫苗推广对减少不必要处方的潜在影响。

局限性

  • 传统成本效果分析仅聚焦避免的伤寒病例及相关成本,未纳入疫苗对非特异性急性发热患者治疗的影响。
  • 本文未报告原始研究数据、样本量或统计检验结果,结论基于既有分析与作者观点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid fever is an acute systemic infectious disease responsible for an estimated 12-20 million illnesses and over 150 000 deaths annually. In March, 2018, a new recommendation was issued by WHO for the programmatic use of typhoid conjugate vaccines in endemic countries. Health economic analyses of typhoid vaccines have informed funding decisions and national policies regarding vaccine rollout. However, by focusing only on averted typhoid cases and their associated costs, traditional cost-effectiveness analyses might underestimate crucial benefits of typhoid vaccination programmes, because the potential effect of typhoid vaccines on the treatment of patients with non-specific acute febrile illnesses is not considered. For every true case of typhoid fever, three to 25 patients without typhoid disease are treated with antimicrobials unnecessarily, conservatively amounting to more than 50 million prescriptions per year. Antimicrobials for suspected typhoid might therefore be an important selective pressure for the emergence and spread of antimicrobial resistance globally. We propose that large-scale, more aggressive typhoid vaccination programmes-including catch-up campaigns in children up to 15 years of age, and vaccination in lower incidence settings-have the potential to reduce the overuse of antimicrobials and thereby reduce antimicrobial resistance in many bacterial pathogens. Funding bodies and national governments must therefore consider the potential for broad reductions in antimicrobial use and resistance in decisions related to the rollout of typhoid conjugate vaccines.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Andrews JR, Baker S, Marks F, et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infect Dis. 2018. PMID: 30170987. doi:10.1016/S1473-3099(18)30350-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。